

- 2 -

In the Specification:

Amendment to the Title of the Invention

At page 1, please replace the title which reads: [Bispecific Molecules Having Clinical Utilities] with the following new title: --Bispecific Molecules For Use in Inducing Antibody Dependent Effector Cell-Mediated Cytotoxicity--.

Amendment to the Detailed Description

At page 5, line 6, please insert the following sentence after the phrase "ATCC Accession No. HB9469" - The hybridoma producing mAb 22 is available from the American Type Culture Collection, ATCC Accession No. HB12147.

Amendment to the Abstract of the Invention

At page 16, please replace the title which reads: [Bispecific Molecules Having Clinical Utilities] with the following new title: --Bispecific Molecules For Use in Inducing Antibody Dependent Effector Cell-Mediated Cytotoxicity--.

At page 16, please delete the current abstract which reads:

[Bispecific molecules comprising a target cell specific ligand and an effector cell specific antibody or functional antibody fragment are disclosed.]

and add the following new abstract:

• Bispecific molecules comprising a non-immunoglobulin tumor cell specific ligand and an antibody which binds the Fc receptor of an effector cell at a site that is not inhibited by endogenous immunoglobulin are disclosed. The bispecific molecules can be used to induce a specific antibody dependent effector cell-mediated cytotoxicity against tumor cells, such as small cell lung carcinoma (SCLC) cells, either *in vivo* or *in vitro*.